251085-87-7

Basic information

• Product Name: Methyl 5-bromo-2-chlorobenzoate
• Synonyms: 2-Chloro-5-broMobenzoic acid Methyl ester
• CAS NO: 251085-87-7
• Molecular Formula: C₈H₆BrClO₂
• Molecular Weight: 249.5
• Product Categories: Acids & Esters;Bromine Compounds;Chlorine Compounds
• Mol File: 251085-87-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 43-44 °C
• Boiling Point: 276.043 °C at 760 mmHg
• Flash Point: 120.747 °C
• Appearance: /
• Density: 1.605 g/cm³
• Vapor Pressure: 0.00491mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 5-bromo-2-chlorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-bromo-2-chlorobenzoate(251085-87-7)
• EPA Substance Registry System: Methyl 5-bromo-2-chlorobenzoate(251085-87-7)

Safety Data

• Hazardous Substances Data: 251085-87-7(Hazardous Substances Data)

Usage

General Description

Methyl 5-bromo-2-chlorobenzoate is an organic chemical compound, belonging to the class of compounds known as benzoic acids and derivatives. It is characterized by its structural components which include a bromine and a chlorine atom on a benzene ring, with a methyl ester attached to a carboxylic acid group. This chemical is used primarily in the field of organic chemistry, often as a reagent in certain chemical reactions. It is typically in the form of a solid and poses certain hazards such as causing serious eye irritation and may cause respiratory irritation, requiring careful handling and storage. Due to their high reactivity, esters like methyl 5-bromo-2-chlorobenzoate play a vital role in the production of pharmaceuticals, polymers, and many other chemical products.

InChI:InChI=1/C8H6BrClO2/c1-12-8(11)6-4-5(9)2-3-7(6)10/h2-4H,1H3

Upstream product

• 67-56-1 methanol 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 189628-37-3 2-chloro-5-bromobenzaldehyde 
• 149965-40-2 5-bromo-2-chlorobenzyl alcohol 
• 478374-91-3 2-(azidomethyl)-4-bromo-1-chlorobenzene 
• 1026202-39-0 methanesulfonic acid 5-bromo-2-chlorobenzyl ester 
• 914105-96-7 3-(2-chloro-5-cyanophenyl)-5-(4-cyanophenyl)isoxazole 
• 914106-15-3 3-(5-bromo-2-chlorophenyl)-5-(4-cyanophenyl)isoxazole 
• 914106-04-0 5-bromo-2-chlorobenzaldehyde chlorooxime 
• 914106-40-4 5-bromo-2-chlorobenzaldoxime 
• 272130-85-5 methyl 2-chloro-5-ethenylbenzoate 

Relevant articles and documents

SUBSTITUTED CYCLOPROPYL-2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME

The present disclosure includes novel substituted cyclopropyl-2,2'-bipyrimidinyl compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.

5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma

Through a phenotypic high-throughput screen using a serum response element luciferase promoter, we identified a novel 5-aryl-1,3,4-oxadiazol-2-ylthiopropionic acid lead inhibitor of Rho/myocardin-related transcription factor (MRTF)/serum response factor (SRF)-mediated gene transcription with good potency (IC50 = 180 nM). We were able to rapidly improve the cellular potency by 5 orders of magnitude guided by sharply defined and synergistic SAR. The remarkable potency and depth of the SAR, as well as the relatively low molecular weight of the series, suggests, but does not prove, that binding to the unknown molecular target may be occurring through a covalent mechanism. The series nevertheless has no observable cytotoxicity up to 100 μM. Ensuing pharmacokinetic optimization resulted in the development of two potent and orally bioavailable anti-fibrotic agents that were capable of dose-dependently reducing connective tissue growth factor gene expression in vitro as well as significantly reducing the development of bleomycin-induced dermal fibrosis in mice in vivo.

SUBSTITUTED ISOXAZOLINE DERIVATIVES

This invention recites substituted isoxazoline derivatives of Formula (1) or a veterinarily acceptable salt thereof, with parasiticidal activity, compositions thereof, and their use as a parasiticide in animals or birds where R1a, R1b/sup